ESTA Stock Forecast & Price Target

Establishment Labs Hldgs is viewed positively because its U.S. Motiva launch continues to outperform, with seven consecutive quarters of U.S. strength, surgeon trainings surpassing the prior full-year target of 260 by 1Q26, and new account openings topping 1,700 in the first ~400 days. The company also appears positioned for a 3Q revenue beat, with 2026 revenue modeled at about $270M, or +28% y/y, while improving direct-market mix, distributor discipline, and better ordering practices should support stronger visibility and margins. Additionally, the stock has multiple catalysts, including potential FDA approval for the reconstruction indication and an updated 5+ year exclusive silicone supply contract, which could remove an overhang and reinforce a path to sustained growth.

Establishment Labs Hldgs is facing a weak fundamental backdrop driven by poor sales of its Motiva implant, its lead product, alongside a failure to secure additional regulatory clearances that could have broadened growth. Management’s conservative guidance, with no meaningful recovery assumptions embedded in 2H26 and no contribution from the Middle East in 1Q26, signals limited near-term momentum even though the region is under 5% of revenue. The outlook is further pressured by intensified competition from better-capitalized rivals, delayed profitability targets that strain the capital position, reliance on a single silicone supplier, and difficulties attracting and retaining key executives and sales staff.